Update of carcinogenicity studies in animals and humans of 535 marketed pharmaceuticals

Mutation Research - Reviews in Mutation Research

Volumn 750, Issue 1, 2012, Pages 1-51

  Brambilla, Giovanni ^a   Mattioli, Francesca ^a   Robbiano, Luigi ^a   Martelli, Antonietta ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Carcinogenicity of 535 marketed pharmaceuticals; Carcinogenicity studies in animals; Carcinogenicity studies in humans

Indexed keywords

ABACAVIR; ABARELIX; ACAMPROSATE; ACARBOSE; ACEBUTOLOL; ACETYLMETHADOL; ACICLOVIR; ACRIVASTINE; ACTARIT; ADAPALENE; ADEFOVIR; ALBENDAZOLE; ALENDRONIC ACID; ALFUZOSIN; ALLOPURINOL; ALMOTRIPTAN; ALOSETRON; ALPRAZOLAM; ALPRENOLOL; ALUMINUM HYDROXIDE; AMILORIDE; AMINOPHENAZONE; AMIODARONE; AMLEXANOX; AMLODIPINE; AMOBARBITAL; DOXORUBICIN; SALBUTAMOL; UNINDEXED DRUG;

CARCINOGEN TESTING; DRUG CARCINOGENICITY; GENOTOXICITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; DRUG TOXICITY; HUMANS; PHARMACEUTICAL PREPARATIONS;

ANIMALIA;

EID: 84155167025     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2011.09.002     Document Type: Review

References (230)

1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guideline for Industry. S2A. Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals, April 1996.
2. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry. S2B. Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals, July 1997.
3. Müller L., Kikuchi Y., Probst G., Schechtman L., Shimada H., Sofuni T., Tweats D.D. ICH-harmonized guidance on genotoxicity testing of pharmaceuticals; evolution, reasoning and impact. Mutat. Res. 1999, 436:195-225.
4. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidelines for Industry. S1A. The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals, March 1996.
5. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry. S1B. Testing for Carcinogenicity of Pharmaceuticals, July 1997.
6. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans 1972-2010, vol. 1-99. IARC, Lyon, France.
7. Snyder R.D., Green J.W. A review of the genotoxicity of marketed pharmaceuticals. Mutat. Res. 2001, 488:151-169.
8. U.S. Department of Health and Human Sciences, Registry of Toxic Effects of Chemical Substances, 1985-1986 ed., U.S. Department of Health and Human Sciences, Washington, 1988.
9. Physicians' Desk Reference, 59th ed., Thomson PDR, Montvale, NJ, USA, 2005.
10. http://www.toxnet.nlm.nih.gov/.
11. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Natl. Toxicol. Program Tech. Rep. Ser., 50, 1978.
12. Rosenkrantz H., Fleischman R.W. In vivo carcinogenicity assay of l-a-acetylmethadol HCl in rodents. Fundam. Appl. Toxicol. 1988, 11:629-639.
13. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 76, Some Antiviral and Antineoplastic Drugs, and other Pharmaceutical Agents 2000, IARC, Lyon, France.
14. Horak F., Stübner U.P. Comparative tolerability of second generation antihistamines. Drug Saf. 1999, 20:385-401.
15. Trutter J., Machotka S.V., Alsaker R.D., Sumi N., Toshida K. Carcinogenicity study of a new orally active antirheumatic drug 4 acetylaminophenylacetic acid (MS-932) in mice. Oyo Yakuri 1990, 40:325-335.
16. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 10, Some Naturally Occurring Substances 1976, IARC, Lyon, France.
17. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, Suppl. 7, Overall Evaluation of Carcinogenicity: An Updating of IARC Monographs 1987, vol. 1-42. IARC, Lyon, France.
18. Center for Drugs Evaluation and Research, http://www.fda.gov.cder/.
19. Coogan P.F., Rosenberg L., Palmer J.R., Strom B.L., Stolley P.D., Zauber A.G., Shapiro S. Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines (United States). Cancer Causes Control 2000, 11.
20. Harlow B.L., Cramer D.W. Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combines case-control studies (Massachusetts, United States). Cancer Causes Control 1995, 6:130-134.
21. FDA Status report on beta-blockers. FDA Drug Bull. 1978, 8:13.
22. PCS INCHEM, http://www.inchem.org/.
23. Grossman E., Messerli F.H., Goldbourt U. Carcinogenicity of cardiovascular drugs. Curr. Hypertens. Rep. 1999, 1:212-218.
24. Inai K., Kobuke T., Fujihara M., Yonehara S., Takemoto T., Tsuya T., Yamamoto A., Tachiyama Y., Izumi K., Tokuoka S. Lack of tumorigenicity of aminopyrine orallty administered to B6C3F1 mice. Jpn. J. Cancer Res. 1990, 81:122-128.
25. http://www.potency.berkeley.edu/.
26. Grossman E., Messerli F.H., Goldbourt U. Carcinogenicity of antihypertensive therapy. Curr. Hypertens. Rep. 2002, 4:195-201.
27. Bahl S., Cotterchio M., Kreiger N. Use of antidepressant medication and the possibile association with breast cancer risk. A review. Psychother. Psychosom. 2003, 72:185-194.
28. Chien C., Li C.I., Heckbert S.R., Malone K.E., Boudreau D.M., Daling J.R. Antidepressant use and breast cancer risk. Breast Cancer Res. Treat. 2006, 95:131-140.
29. Coogan P.F. Review of the epidemiological literature on antidepressant use and breast cancer risk. Expert. Rev. Neurother. 2006, 6:1363-1374.
30. Gonzàles-Pérez A., Garcìa Rodrìguez L.A. Breast cancer risk among users of antidepressant medications. Epidemiology 2005, 16:101-105.
31. Kurdyak P.A., Gnam W.H., Streiner D.L. Antidepressants and the risk of breast cancer. Can. J. Psychiatry 2002, 47:966-970.
32. Moorman P.G., Berchuck A., Calingaert B., Halabi S., Schuildkraut J.M. Antidepressant medication use [corrected] and risk of ovarian cancer. Obstet. Gynecol. 2005, 105:725-730.
33. Xu W., Tamim H., Shapiro S., Stang M.R., Collet J.P. Use of antidepressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol. 2006, 7:301-308.
34. Sternbach H. Are antidepressants carcinogenic? A review of preclinical and clinical studies. J. Clin. Psychiatry 2003, 64:1153-1162.
35. Hoover R., Fraumeni J.F. Drugs in clinical use which cause cancer. J. Clin. Pharmacol. 1975, 15:16-23.
36. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 50, Pharmaceutical Drugs 1990, IARC, Lyon, France.
37. Kelly J.P., Coogan P., Strom B.L., Rosenberg L. Lung cancer and regular use of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Pharmacoepidemiol. Drug Saf. 2008, 17:322-327.
38. Feskanich D., Bain C., Chan A.T., Pandeya N., Speizer F.E., Colditz G.A. Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency. Br. J. Cancer 2007, 97:1295-1299.
39. Gierach G.L., Lacey J.V., Schatzkin A., Leitzmann M.F., Richesson D., Hollenbeck A.R., Brinton L.A. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health - AARP diet and Health Study. Breast Cancer Res. 2008, 10:R38.
40. Mangiapane S., Blettner M., Schlattmann P. Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol. Drug Saf. 2008, 17:115-124.
41. Friis S., Thomassen L., Sørensen H.T., Tjønneland A., Overvad K., Cronin-Fenton D.P., Vogel U., McLaughlin J.K., Blot W.J., Olsen J.H. Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur. J. Cancer Prev. 2008, 17:88-96.
42. Steineck G., Wiholm B.E., Gerhardsson de Verdier M. Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population-based case-control study. Acta Oncol. 1995, 34:741-748.
43. Gago-Dominguez M., Yuan J.M., Castelao J.E., Ross R.K., Yu M.C. Regular use of analgesics is a risk factor for renal cell carcinoma. Br. J. Cancer 1999, 81:542-548.
44. Hoover R., Fraumeni J.F. Drug-induced cancer. Cancer 1981, 47:1071-1080.
45. Sadeghi S., Bain C.J., Pandeya N., Webb P.M., Green A.C., Whiteman D.C. Australian Cancer Study, Collaborators (78), Aspirin, nonsteroidal anti-inflammatory drugs, and the risk of cancer of the esophagus. Cancer Epidemiol. Biomarkers Prev. 2008, 17:1169-1178.
46. Viswanathan A.N., Feskanich D., Schernhammer E.S., Hankinson S.E. Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res. 2008, 68:2507-2513.
47. Hannibal C.G, Rossing M.A., Wicklund K.G., Cushing-Haugen K.L. Analgesic drug use and risk of epithelial ovarian cancer. Am. J. Epidemiol. 2008, 167:1430-1437.
48. Liu E., Sakoda L.C., Gao Y.T., Rashid A., Shen M.C., Wang B.S., Deng J., Han T.Q., Zhang B.H., Fraumeni J.F., Hsing A.W. Aspirin use and risk of biliary tract cancer: a population-based study in Shanghai, China. Cancer Epidemiol. Biomarkers Prev. 2005, 14:1315-1318.
49. Chan A.T., Giovannucci E.L., Meyerhardt J.A., Schernhammer E.S., Wu K., Fuchs C.S. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008, 134:21-28.
50. Friedman G.D., Ury H.K. Screening for possible drug carcinogenicity: second report of findings. J. Natl. Cancer Inst. 1983, 71:1165-1171.
51. Benze J., Gypen L., Vandenberghe J., Lampo A., De Coster R., Bowden C., Van Cauteren H. Carcinogenicity studies of astemizole in mice and rats. Cancer Res. 1995, 55:5589-5594.
52. Jackson C.D., Fishbein L. A toxicological review of beta-adrenergic blockers. Fundam. Appl. Toxicol. 1986, 6:395-422.
53. Boudreau D.M., Gardner J.S., Malone K.E., Heckbert S.R., Blough D.K., Daling J.R. The association between 3-hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast cancer risk among postmenopausal women: a case-control study. Cancer 2004, 100:2308-2316.
54. Kaye J.A., Meier C.R., Walker A.M., Jick H. Statin use, hyperlipidaemia, and the risk of breast cancer. Br. J. Cancer 2002, 86:1436-1439.
55. Friis S., Olsen J.H. Statin use and cancer risk: an epidemiologic review. Cancer Invest. 2006, 24:413-424.
56. Newman T.B., Hulley S.B. Carcinogenicity of lipid-lowering drugs. JAMA 1996, 275:55-60.
57. Iwata H., Matsuo K., Hara S., Takeuchi K., Aoyama T., Murashige N., Kanda Y., Mori S., Suzuki R., Tachibana S., Yamane M., Odawara M., Mutou Y., Kami M. Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci. 2006, 97:133-138.
58. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 13, Some Miscellaneous Pharmaceutilal Substances 1977, IARC, Lyon, France.
59. Adrian R.W., Jahn U. Testing of dimetacrine and azapropazone in a carcinogen test in mice. Arzneim.-Forsch. 1969, 19:1997-1998.
60. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 26, Some Antineoplastic and Immunosuppressive Agents 1981, IARC, Lyon, France.
61. Preussmann R. Carcinogenicity of nitrosoureas in humans. IARC Sci. Publ. 1986, 78:223-229.
62. Janssen P.A.J., Niemegeers C.J.E., Schellekens K.H.L., Marsboom R.H.M., Herin V.V., Amery W.K.P., Admiraal P.V., Bosker J.T., Crul J.F., Pearce C., Zegveld C. Bezitramide (R 4845), a new potent and orally long-acting analgesic compound. Arzneim.-Forsch. 1971, 21:862-867.
63. Stoll R.E, Blanchard K.T., Stoltz J.H., Majerka J.B., Furst S., Lilly P.D., Mennear J.H. Phenolphthalein and bisacodyl: assessment of genotoxic and carcinogenic responses in heterozygous p53 (+/-) mice and Syrian hamstyer embryo assay. Toxicol. Sci. 2006, 90:440-450.
64. Hewett C., Ellenberger J., Kollmer H., Kreuzer H., Niggeschulze A., Stotzer H. Safety assessment of brotizolam. Arzneim.-Forsch. 1986, 36:592-596.
65. McClain R.M., Dammers K.D. Toxicological evaluation of bumetanide, a potent diuretic agent. J. Clin. Pharmacol. 1981, 21:543-554.
66. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 51, Coffee, Tea, Mate, Methylxantines and Methylglyoxal 1991, IARC, Lyon, France.
67. Takayama S., Kuwabara N. Long-term study of the effect of caffeine in Wistar rats. Gann 1982, 73:365-371.
68. Mohr U., Altoff J., Ketkar M.B., Conradt P., Morgareidge K. The influence of caffeine on tumor incidence in Sprague-Dawley rats. Food Chem. Toxicol. 1984, 22:377-382.
69. Pozniak P.C. The carcinogenicity of caffeine and coffee: a revew. J. Am. Diet. Assoc. 1985, 85:1127-1133.
70. Tavani A., Negri E., Franceschi S., Salamini R., La Vecchia C. Coffee consumption and risk of non-Hodgkin's lymphoma. Eur. J. Cancer Prev. 1994, 3:351-356.
71. National Toxicology Program Bioassay of carbromal for possible carcinogenicity. Natl. Cancer Inst. Carcinog. Tech. Rep. Ser. 1979, 173:1-135.
72. Lang W. Zur toxikologie von carteolol. Arzneim.-Forsch. 1983, 33:290-295.
73. Kurosumi M., Hatori M., Nishino H. Carcinogenicity of carteolol hydrochloride in Balb/c mice. Il Farm. Ed. Prat. 1979, 34:202-209.
74. Tamagawa M., Numoto T., Tanaka N., Nishino H.H. Reproduction study of carteolol hydochloride in mice. Part 2: peri- and postnatal toxicity. J. Toxicol. Sci. 1979, 4:59-77.
75. Moorman P.G., Grubber J.M., Millikan R.C., Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003, 14:915-922.
76. Duan L., Wu A.H., Sullivan-Halley J., Bernstein L. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastri adenocarcinomas in Los Angeles Country. Cancer Epidemiol. Biomarkers Prev. 2008, 17:126-134.
77. Markiewicz V., Tompkins C., Mehdi N., Hubmer S., Payne B.J., Sumi N. Range finding toxicity and carcinogenicity studies of a new beta-adrenoceptors blocking agent celiprolol in mice. Oyo Yakuri 1989, 38:421-434.
78. Wendtlandt W., Pittner H. Toxikologische Prufung von celiprolol, einem kardioselektive β-Rezeptoren-Blocker. Arzneim.-Forsch. 1983, 33:41-49.
79. Markiewicz V., Tompkins C., Mehdi N., Hubmer S., Payne B.J., Sumi N. Range finding toxicity and carcinogenicity studies of a new beta-adrenoceptors blocking agent celiprolol in rats. Oyo Yakuri 1989, 38:407-420.
80. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 84, Some Drinking-water Disinfectants and Contaminants, including Arsenic 2004, IARC, Lyon, France.
81. Scirus, http://www.scirus.com/.
82. Haselkorn T., Whittemore A.S., Udaltsova N., Friedman G.D. Short-term chloral hydrate administration and cancer in humans. Drug Saf. 2006, 29:67-77.
83. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 21, Sex Hormones (II) 1979, IARC, Lyon, France.
84. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 72, Hormonal Contraception and Post-menopausal Hormonal Therapy 1999, IARC, Lyon, France.
85. National Toxicology Program Toxicology and carcinogenesis studies of chlorpheniramine maleate (CAS No. 113-92-8) in F344/N rats and B6C3F1 mice (gavage studies). Natl. Toxicol. Program Tech. Rep. Ser. 1986, 317:1-148.
86. Lijinsky W. Induction of tumours in rats by feeding nitrosable amines together with sodium nitrite. Food Chem. Toxicol. 1984, 22:715-720.
87. Nesnow S., Argus M., Bergman H., Chu K., Frith C., Helmers T., McGaughy R., Ray V., Slaga T.J., Tennant R., Weisburger E. Chemical carcinogens. A review and analysis of the literature of selected chemicals and the establishment of the Gene-Tox Carcinogen Data Base. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat. Res. 1986, 185:1-195.
88. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 45, 1978.
89. Rao M.S., Lalwani N.D., Watanabe T.K., Reddy J.K. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferators. Cancer Res. 1984, 44:1072-1076.
90. Greene M.H. Is cisplatin a human carcinogen?. J. Natl. Cancer Inst. 1992, 84:306-312.
91. Steingart A.B., Cotterchio M. Do antidepressants cause, promote, or inhibit cancers?. J. Clin. Epidemiol. 1995, 48:1407-1412.
92. Snyder R.D. A review and investigation into the mechanistic basis of the genotoxicity of antihistamines. Mutat. Res. 1988, 411:235-248.
93. Barzaghi F., Fournex R., Mantegazza P. Pharmacological and toxicological properties of clobazam (1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2-4-diketo-3H-1,5-benzodiazepine), a new psychotherapeutic agent. Arzneim.-Forsch. 1973, 23:683-686.
94. Miyawaki I., Moriyasu M., Funabashim H., Yasuba M., Matsuoka N. Mechanism of clobazam-induced thyroidal oncogenesis in male rats. Toxicol. Lett. 2003, 145:291-301.
95. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 24, Some Pharmaceutical Drugs 1980, IARC, Lyon, France.
96. Diwan B.A., Lubet R.A., Nims R.W., Klaunig J.E., Weghorst C.M., Henneman J.R., Ward J.M., Rice J.M. Lack of promoting effect of clonazepam on the development of N-nitrosodiethylamine-initiated hepatocellular tumors in mice is correlated with its inability to inhibit cell-to-cell communication in mouse hepatocytes. Carcinogenesis 1989, 10:1719-1724.
97. Blum J.E., Haefely W., Jalfre M., Pole P., Schärer K. Parmakologie und toxikologie des antiepilecticum clonazepam. Arzneim.-Forsch. 1973, 23:377-400.
98. United States National Toxicology Program, Toxicology and carcinogenesis studies of codeine (CAS No. 76-57-3) in F344/N rats and B6C3F1 mice (feed studies), NTP TR-455, 1996.
99. Fraumeni J.F., Miller R.W. Drug-induced cancer. J. Natl. Cancer Inst. 1972, 48:1267-1270.
100. Rieche K. Carcinogenicity of antineplastic agents in man. Cancer Treat. Rev. 1984, 11:39-67.
101. Friedman G.D., Jiang S.F., Udaltsova N., Quesenberry C.P., Chan J., Habel L.A. Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity. Int. J. Cancer 2009, 125:2173-2178.
102. Wall R.L., Clausen K.P. Carcinoma of the urinary bladder in patients receiving cyclophosphamide. N. Engl. J. Med. 1975, 293:271-273.
103. Kälble T. Etiopathology, risk factors, environmental influences and epidemiology of bladder cancer. Urologie 2001, 40:447-450.
104. Donatsch P., Madorin M., Rüttimann G., Schön H., Wilson J. Toxicological evaluation of cyclosporine A. Arch. Toxicol. 1983, 53:107-141.
105. Ryffel B. The carcinogenicity of ciclosporin. Toxicology 1992, 73:1-22.
106. Mori M., Sugie S., Niwa K., Yoshimi N., Tanaka T., Hironi I. Carcinogenicity of of chrysazin in large intestine and liver of mice. Gann 1986, 77:871-876.
107. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 20, 1977.
108. Fleming C.M., Persad R., Kaisary A., Smith P., Adedoyin A., Porter J., Wilkinson G.R., Branch R.A. Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer. Pharmacogenetics 1994, 4:199-207.
109. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 66, Some Pharmaceutical Drugs 1996, IARC, Lyon, France.
110. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 355, 1989.
111. Kumagai H., Kawaura A., Shibaya M., Otsuka H. Carcinogenicity of dipyrone in (C57BL/6×C3H)F1 mice. J. Natl. Cancer Inst. 1983, 71:1295-1297.
112. Izumi K., Sano N., Otsuka H., Kinouchi T., Ohnishi Y. Tumor promoting potential in male F344 rats and mutagenicity in Salmonella typhimourium of dipyrone. Carcinogenesis 1991, 12:1221-1225.
113. Donabauier H.H., Kief H., Kramer M., Krieg K., Mayer D., Schutz E. Investigations on the carcinogenicity of dipyrone in rats. Toxicol. Appl. Pharmacol. 1985, 81:443-451.
114. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 12, Some Carbamates, Thiocarbamates and Carbazides 1976, IARC, Lyon, France.
115. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 166, 1979.
116. Borelli G., Bertoli D., Chieco P. Carcinogenicity study of doxefazepam administered in the diet in Sprague-Dawley rats. Fundam. Appl. Toxicol. 1990, 15:82-92.
117. Jackson C.D., Sheldon W. Two-year toxicity study of doxylamine succinate in B6C3F1 mice. J. Am. Coll. Toxicol. 1993, 12:311-321.
118. Jackson C.D., N B. Blackweel, 2-year toxicity study of doxylamine succinate in the Fischer 344 rats. J. Am. Coll. Toxicol 1993, 12:1-11.
119. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 446, 1996.
120. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 307, 1986.
121. Kimura E.T., Fort F.L., Buratto B., Tekeli S., Kesterson J.W., Heyman I.A., Cusick P.K. Carcinogenic evaluation of estazolam via diet in CD strain Sprague-Dawley rats and B6C3F1 mice for 2 years. Fundam. Appl. Toxicol. 1984, 4:827-842.
122. D.F. Kripke, Evidence that new hypnotics cause cancer, Department of Psychiatry University of California, 2006, unpublished data.
123. Naito M., Ito A., Watanabe H., Kawashima K., Anyama H. Carcinogenicity of o-ethoxybenzamide in (C57BL6N×C3H/HeN)F1 mice. J. Natl. Cancer Inst. 1986, 76:115-118.
124. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 46, 1978.
125. Wrenn J.M., Inhelder J.L., Hemm R.D., Pollock J.J., Sumi N. Eighteen month carcinogenicity study of etodolac, a nonsteroidal anti-inflammatory agent, in Charles River CD-1 mice. Oyo Yakuri 1991, 41:113-128.
126. Koyama T., Izawa Y., Wada H., Makita T., Hashimoto Y., Enomoto M. Toxicological aspects of feprazone, a new non-steroidal anti-inflammatory drug. Toxicol. Appl. Pharmacol. 1982, 64:255-270.
127. Bendele R.A., Adams E.R., Hoffman W.P., Gries C.L., Morton D.M. Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res. 1992, 52:6931-6935.
128. Shoyab M. Enhancement by fluphenazine of dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats. Cancer Lett. 1983, 18:297-303.
129. Robison R.L., Suter W., Cox R.H. Carcinogenicity and mutagenicity studies with fluvastatin, a new entirely synthetic HMG-CoA reductase inhibitor. Fundam. Appl. Toxicol. 1994, 23:9-20.
130. Kersten B., Kasper P., Brendler-Schwaab S.Y., Muller R. Use of the photomicronucleus assay in Chinese hamster V79 cells to study photochemical genotoxicity. Mutat. Res. 2002, 519:49-66.
131. National Toxicology Program, Toxicology and carcinogenesis studies of furosemide (CAS No. 54-31-9) in F344/N rats and B6C3F1 mice (feed studies). Natl. Toxicol. Program Tech. Rep. Ser. 365: 1-90, 1989.
132. Bucher J.R., Huff J., Haseman J.K., Euistis S.L., Davis W.E., Meierhenry E.F. Toxicology and carcinogenicity studies of diuretics in F344 rats and B6C3F1 mice. Part 2: furosemide. J. Appl. Toxicol. 1990, 10:369-378.
133. Sigler R.E., Gough A.W., De La Iglesia F.A. Pancreatic acinar cell neoplasia in male Wistar rats following 2 years of gabapentin exposure. Toxicology 1995, 98:73-82.
134. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 79, Some Thyrotropic Agents 2001, IARC, Lyon, France.
135. Micromedex Thomson Health Care USPDI - Drug information for Health Care Professional 2002, vol. 1. Micromedex Thomson Health Care, Greenwood Village, CO. 22nd ed.
136. Toth B. Tumorigenic effect of 1-hydrazinophthalazine hydrochloride in mice. J. Natl. Cancer Inst. 1978, 61:1363-1365.
137. Gershbein L.L., Rao K.C. Action of hydrazine drugs in tumor-free and 1,2-dimethylhydrazine treated male rats. Oncol. Res. 1992, 4:121-127.
138. Kaufman D.W., Kelly J.P., Rosenberg L., Stolley P.D., Schottenfeld D., Shapiro S. Hydralazine and breast cancer. J. Natl. Cancer Inst. 1987, 78:243-246.
139. Kaufman D.W., Kelly J.P., Rosenberg L., Stolley P.D., Warshauer M.E., Shapiro S. Hydralazine use in relation to cancers of the lung, colon, and rectum. Eur. J. Clin. Pharmacol. 1989, 36:259-264.
140. National Toxicology Program, Toxicology and carcinogenesis studies of hydrochlorothiazide (CAS No. 58-93-5) in F344/N rats and B6C3F1 mice (feed studies) Natl. Toxicol. Program Tech. Rep. Ser. 357, 1989.
141. Bucher J.R., Huff J., Hasenman J.K., Eustis S.L., Elwell M.R., Davis W.E., Meierhenry E.F. Toxicology and carcinogenicity studies of diuretics in F344 rats and B6C3F1 mice. Part 1: hydrochlorothiazide. J. Appl. Toxicol. 1990, 10:359-367.
142. Lijinsky W., Reuber M.D. Pathological effects of chronic administration of hydrochlorothiazide with and without sodium nitrite in F344 rats. Toxicol. Ind. Health 1987, 3:413-422.
143. Sanchez-Palacios C., Guitart J. Hydroxyurea-associated squamous dysplasia. J. Am. Acad. Dermatol. 2004, 51:293-300.
144. National Toxicology Program, Toxicology and carcinogenesis studies of scopolamine hydrobromide in F344/N rats and B6C3F1 mice (gavage studies), Natl. Toxicol. Program Tech. Rep. Ser. 445, 1977.
145. Milman H.A. Possible contribution of indomethacin to the carcinogenicity of nongenotoxic bladder carcinogens that cause bladder calculi. Drug Chem. Toxicol. 2007, 30:161-166.
146. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 4, Some Aromatic Amines, Hydrazine and Related Substances, N-nitroso compounds, and miscellaneous alkylating agents 1974, IARC, Lyon, France.
147. Clemmesen J., Hjalgrim-Jensen S. Epidemiological studies of medically used drugs. Arch. Toxicol. Suppl. 1980, 3:19-25.
148. Stott H., Peto J., Stephens R., Fox W. An assessment of the carcinogenicity of isoniazid in patients with pulmonary tuberculosis. Tubercle 1976, 57:1-15.
149. Howe G.R., Lindsay J., Coppock E., Miller A.B. Isoniazid exposure in relation to cancer incidence and mortality in a cohort of tuberculosis patients. Int. J. Epidemiol. 1979, 8:305-312.
150. Mitjavila M.T., Martorell M., Codena R. Toxicological investigation of isonixine. Arzneim.-Forsch. 1977, 27:1460-1464.
151. Rothwell C.E., McGuire E.J., Martin R.A., De La Iglesia F.A. Chronic toxicity and carcinogenicity studies with the beta-adrenoceptor antagonist levobunolol. Fundam. Appl. Toxicol. 1992, 18:353-359.
152. Owen G., Hatfield G.K., Pollock J.J., Steinberg A.J., Tucker W.E., Agersborg H.P. Toxicity studies of Lorazepam, a new benzodiazepine, in animals. Arzneim.-Forsch. 1971, 21:1065-1073.
153. Pohlmeyer-Esch G., Mehdi N., Clarke D., Radhofer-Welte S. Evaluation of chronic oral toxicity and carcinogenic potential of lornoxican in rats. Food Chem. Toxicol. 1997, 35:909-922.
154. Mac Donald J.S., Gerson R.J., Kornbrust D.J., Kloss M.W., Prahalada S., Berry P.H., Alberts A.W., Bokelman D.L. Preclinical evaluation of lovastatin. Am. J. Cardiol. 1988, 62:16J-27J.
155. Osheroff M.R., Ando T., Miyajima H. Oncogenicity study in mice with manidipine hydrochloride [CV4093 (2HCl)]. Yakuri Chiryo 1989, 17(suppl. 4):1205-1216.
156. Osheroff M.R., Ando T., Miyajima H. Oncogenicity study in rats with manidipine hydrochloride [CV4093 (2HCl)]. Yakuri Chiryo 1989, 17(suppl. 4):1217-1231.
157. Sells D.M., Gibson J.P. Carcinogenicity studies with medroxalol hydrochloride in rats and mice. Toxicol. Pathol. 1987, 15:457-467.
158. Gibson J.P., Sells D.M., Cheng H.C., Yuh L. Induction of uterine leiomyomas in mice by medroxalol and prevention by propranolol. Toxicol. Pathol. 1987, 15:468-473.
159. Liang A.P., Levenson A.G., Layde P.M., Shelton J.D., Hatcher R.A., Potts M., Michelson M.J. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA 1983, 249:2909-2912.
160. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 9, Some Aziridines, N-, S- & O-Mustards and Selenium 1975, IARC, Lyon, France.
161. Greenman D.L., Allen R., Dahlgren R., Cronin G.M., Allaben W.T. Chronic toxicity/carcinogenicity study of pyrilamine in B6C3F1 mice. J. Am. Coll. Toxicol. 1995, 14:148-157.
162. Habs M., Shubik P., Eisenbrand G. Carcinogenicity of methapyrilene hydrochloride, mepyramine hydrochloride, thenyldiamine hydrochloride, and pyribenzamine hydrochloride in Sprague-Dawley rats, J. Cancer Res. Clin. Oncol. 1986, 11:71-74.
163. Greenman D.L., Cronin G.M., Dahlgren R., Allen R., Allaben W. Chronic feeding study of pyrilamine in Fisher 344 rats. Fundam. Appl. Toxicol. 1995, 25:1-8.
164. Lijinsky W. Chronic toxicity tests of pyrilamine maleate and methapyrilene hydrochloride in F344 rats. Food Chem. Toxicol. 1984, 22:27-30.
165. Rosenkrantz H., Fleischman R.W. In vivo carcinogenicity assay of DL-methadone HCl in rodents. Fundam. Appl. Toxicol. 1988, 11:640-651.
166. Lijinsky W., Reuger M.D., Blackwell B.N. Liver tumours induced in rats by oral administration of the antihistamine methapyrilene hydrochloride. Science 1980, 209:817-819. 19.
167. United States National Toxicology Program, Toxicology and carcinogenesis studies of alpha-methyldopa sesquihydrate (CAS No. 41372-08-01) in F344/N rats and B6C3F1 mice (feed studies). Natl. Toxicol. Program Tech. Rep. Ser. 348: 1-184, 1989.
168. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, TR-439, 1995.
169. Bendesky A., Menéndez D., Ostrosky-Wegman P. Is metronidazole carcinogenic?. Mutat. Res. 2002, 511:133-144.
170. Falagas M.E., Walker A.M., Jick H., Ruthazer R., Griffith J., Snydman D.R. Late incidence of cancer after metronidazole use: a matched metronidazole user/nonuser study. Clin. Infect. Dis. 1998, 26:384-388.
171. Finegold S.M. Metronidazole. Adv. Intern. Med. 1980, 93:585-587.
172. Friehe H., Ney P. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Arzneim.-Forsch. 1997, 47:132-144.
173. Friesen M., O'Neill I.K., Malaveille C., Garren L., Hautefeuille A., Cabral J.R.P., Galendo D., Lasne C., Sala M., Chouroulinkov I., Mohr U., Turusov V., Day N.E., Bartsch H. Characterization and identification of 6 mutagens in opium pyrolysates implicated in oesophageal cancer in Iran. Mutat. Res. 1985, 150:177-191.
174. Sibley P.L., Keim G.R., Kulesza J.S., Murphy B.F., Myhre J.L., Parish H.M., Yoon Y.H., Zaidi I.H. Preclinical toxicologic evaluation of nadolol, a new β-adrenergic antagonist. Toxicol. Appl. Pharmacol. 1978, 44:379-389.
175. Ahr H.J., Bomhard E., Mager H., Schlüter G. Calcium channel blockers and cancer in three preclinical evidence for an association. Cardiology 1997, 88(suppl. 3):68-72.
176. Tamano S., Ward J.M., Diwan B.A., Keefer L.K., Weghorst C.M., Calvert R.J., Henneman J.R., Ramljak D., Rice J.M. Histogenesis and the role of p53 and K-ras mutations in hepatocarcinogenesis by glyceryl trinitrate (nitroglycerin) in male F344 rats. Carcinogenesis 1996, 17:2477-2486.
177. Eissele R., Arnold R. Risk for developing tumors in therapy with the proton pump inhibitor omeprazole. Versicherungsmedizin 1993, 45:126-129.
178. Bucker J.R., Shackelford C.C., Haseman J.K., Johnson J.D., Kurtz R.L., Persing R.L. Carcinogenicity studies of oxazepam in mice. Fundam. Appl. Toxicol. 1994, 23:280-297.
179. United States National Toxicology Program, Toxicology and carcinogenesis studies of Oxazepam (CAS No. 604-75-1) in Swiss-Webster and B6C3F1 mice (feed studies). Natl. Toxicol. Program Tech. Rep. Ser. 443, 1993.
180. United States National Toxicology Program, Toxicology and carcinogenesis studies of Oxazepam (CAS No. 604-75-1) in F344/N rats (feed studies). Natl. Toxicol. Program Tech. Rep. Ser. 468: 1-189, 1998.
181. Bucker J.R., Haseman J.K., Herbert R.A., Ryan M.J. Toxicity and carcinogenicity studies of oxazepam in the Fisher 344 rat. Toxicol. Sci. 1998, 42:1-12.
182. Newberne J.W., Newberne P.M., Gibson J.P., Huffman K.W., Palopoli F.P. Lack of carcinogenicity of oxprenolol, a beta-adrenergic blocking agent. Toxicol. Appl. Pharmacol. 1977, 41:535-546.
183. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 485, 1999.
184. Shuey D.L., Woodland C., Tremblay C., Gregson R., Gerson R.J. Oxymorphone hydrochloride, a potent opioid analgesic, is not carcinogenic in rats or mice. Toxicol. Sci. 2007, 96:162-173.
185. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 73, Some Chemicals that Cause Tumours of the Kidney or Urinary Bladder in Rodents and some other Substances 1999, IARC, Lyon, France.
186. Berg K.J. Paracetamol-kidney and urinary tract: A cause of analgetic nephropathy or cancer?. Tidsskr. Nor. Laegeforen. 1994, 114:1169-1174.
187. McCredie M., Stewart J.H., Day N.E. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int. J. Cancer 1993, 53:245-249.
188. McCredie M., Pommer W., McLaughlin J.K., Stewart J.H., Lindblad P., Mandel J.S., Mellemgaard A., Schlehofer B., Niwa S. International renal-cell cancer study. II. Analgesics. Int. J. Cancer 1995, 60:345-349.
189. Castelao J.E., Yuan J.M., Gago-Dominguez M., Yu M.C., Ross R.K. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br. J. Cancer 2000, 82:1364-1369.
190. Friedman G.D., Ury H.K. Initial screening for carcinogenicity of commonly used drugs. J. Natl. Cancer Inst. 1980, 65:723-733.
191. Cohen S.M., Shirai T., Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand. J. Urol. Nephrol. Suppl. 2000, 205:105-115.
192. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 99, 1978.
193. Friedman G.D. Barbiturates and lung cancer in humans. J. Natl. Cancer Inst. 1981, 67:291-295.
194. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 465, 1996.
195. Stoner G.D., Shimkin M.B., Kniazeff A.J., Weisburger J.H., Weisburger E.K., Gori G.B. Test for carcinogenicity of food additives and chemotherapeutic agents by the pulmonary tumor response in strain A mice. Cancer Res. 1973, 13:3069-3085.
196. National Cancer Institute, Bioassay of Phenoxybenzamine Hydrochloride for Possible Carcinogenicity, Technical Report Series No. 72. U.S. Department of Health, Education, and Welfare, Publication No. (NIH) 78-1322, Washington, DC, U.S, Governmentt Printing Office, 1978.
197. U.S. National Toxicology Program. Toxicology and carcinogenesis studies of phenylbutazone (CAS No. 50-33-9) in F344/N rats and B6C3F1 mice, Natl. Toxicol. Program, Tech. Rep. Ser. 367.
198. Ragnotti G., Presta M., Riboni L., Zavanella T. Liver tumors induced by a new beta-adrenoreceptor blocking agent in female rats. J. Natl. Cancer Inst. 1982, 68:669-672.
199. Dillberger J.E., Cronin N.S., Carr G.J. Prednisone is not a mouse carcinogen. Toxicol. Pathol. 1992, 20:18-26.
200. Faccini J.M., Irisarri E., Monro A.M. A carcinogenicity study in mice of a β-adrenergic antagonist, primidolol: increased total tumor incidence without tissue specificity. Toxicology 1981, 21:279-290.
201. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 476, 2000.
202. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 395, 1991.
203. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 425, 1993.
204. Weikel J.H., Kelòly W.A. Tumorigenicity assay of sotalol hydrochloride in rats and mice. J. Clin. Pharmacol. 1979, 19:591-604.
205. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, TR-77, 1978.
206. Black H.E., Szot R.J., Arthaud L.E., Massa T., Mylecraine L., Klein M., Lake R., Fabry A., Kamimska G.Z., Sinha D.P., Schwartz E. Preclinical safety evaluation of the benzodiazepine quazepam. Arzneim.-Forsch. 1987, 37:906-913.
207. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, vol. 31, Some Food Additives, Feed additives and Naturally Occurring Substances 1983, IARC, Lyon, France.
208. Harwood M., Danielewska-Nikiel B., Borzellaca J.F., Flamm G.W., Williams G.M., Lines T.C. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol. 2007, 45:2179-2205.
209. National Cancer Institute, Bioassay of Reserpine for Possible Carcinogenicity. U.S. Department of Health, Education, and Wlfare, Publication No. (NIH) 80-1749, Washington, DC, U.S, Government Printing Office, 1980.
210. Fitzgerald J.E., De La Iglesia F.A., McGuire E.J. Carcinogenicity studies in rodents and ripazepam, a minor tranquilizing agent. Fundam. Appl. Toxicol. 1984, l41:178-190.
211. Lumb G., Newberne P., Rust J.H., Wagner B. Effects in animals of chronic administration of spironolactone: a review. J. Environ. Pathol. Toxicol. 1978, 1:641-660.
212. Wutzler P., Thust R. Genetic risks of antiviral nucleoside analogue - a survey. Antiviral Res. 2001, 49:55-74.
213. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 460, 1997.
214. Becker J.C., Houben R., Vetter C.S., Bröcker E.B. The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer 2006, 6:7.
215. Hirsimaki P., Aaltonen A., Mantyia E. Toxicity of antiestrogens. Breast J. 2002, 8:92-96.
216. Williams G.M., Jeffrey A.W. Safety assessment of tamoxifen and toremifene. Oncology 1997, 11:41-47.
217. Steams V., Gelman E.P. Does tamoxifen cause cancer in humans?. J. Clin. Oncol. 1998, 16:779-792.
218. Robison R.L., Van Ryzin R.J., Stoll R.E., Jensen R.D., Bagdon R.E. Chronic toxicity/carcinogenesis study of temazepam in mice and rats. Fundam. Appl. Toxicol. 1984, 4:394-405.
219. Gibson J.P., Huffmann K.W., Newberne J.W. Preclinical safety studies with terfenadine. Arzneim.-Forsch. 1982, 32:1179-1184.
220. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 473, 1998.
221. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 51, 1978.
222. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 31, 1977.
223. NCI/NTP Carcinogenesis Technical Report Series, National Cancer Institute/National Toxicology Program, U.S. Department of Health and Human Services, Cancer Inst. Carcinog. Tech. Rep. Ser. 77, 1978.
224. Greenman D.L., Sheldon W., Schieferstein G., Allen R., Allaben W.T. Chronic study of triprolidine for oncogenicity in mice. Fundam. Appl. Toxicol. 1995, 25:138-145.
225. Greenman D.L., Sheldon W., Schieferstein G., Allen R., Allaben W.T. Triprolidine: 104-week feeding study in rats. Fundam. Appl. Toxicol. 1995, 27:223-231.
226. Jin M., Takahashi M., Moto M., Muguruma M., Ito K., Watanabe E., Kemmoki Y., Kono T., Hasumi K., Mitsumori K. Carcinogenic susceptibility of rasH2 mice to troglitazone. Arch. Toxicol. 2007, 81:883-894.
227. Watkins J.R., Gough A.W., McGuire E.J., Goldelthal E., De La Iglesi F.A. Calcium valproate-induced uterine adenocarcinomas in Wistar rats. Toxicology 1992, 71:35-47.
228. Brambilla G., Martelli A. Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. Mutat. Res. 2009, 681:209-229.
229. Rall D.P. Candidate drugs for carcinogenic property studies: procedures. J. Clin. Pharmacol. 1975, 15:1-4.
230. Smith P.G., Jick H. Regular drug use and cancer. J. Natl. Cancer Inst. 1977, 59:1387-1391.